Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

Published Date: 19 Apr 2023

Pediatric patients with solid tumors exhibiting DNA replication stress and/or DNA repair responded favorably to a combination of the investigational ATR inhibitor ceralasertib and the PARP inhibitor olaparib (Lynparza).

Read Full News

Latest News

Rare Tumor in a Rare Location in Patient With Constipation

Could occupational exposure to sawdust explain this case?

ASTRO: American Society for Radiation Oncology

A Surgical First for Removal of an Appendiceal Neoplasm

Technique deemed safe and feasible for selected patients and better than other minimally invasive approaches

What's Behind the Mysterious Chest Pain in Bladder Cancer Patient?

Cardiomyopathy risks interrupting cancer treatment, worsening prognosis

Cancer Deaths Fall, Cases Rise; Diabetes and Cancer Risk; Vitamin C for Cancer

— News, features, and commentary about cancer-related issues

Benign or Malignant? No Way to Tell Radiologically

Case shows importance of accurate preop diagnosis

Todays Updates

Episode 177: Previewing the 2026 NEALS Annual Meeting Marco Meglio, Jinsy A. Andrews, MD, MSc, Nicholas Maragakis, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]

Todays Updates

Episode 177: Previewing the 2026 NEALS Annual Meeting Marco Meglio, Jinsy A. Andrews, MD, MSc, Nicholas Maragakis, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]

Latest News

Could occupational exposure to sawdust explain this case?

Technique deemed safe and feasible for selected patients and better than other minimally invasive approaches

Cardiomyopathy risks interrupting cancer treatment, worsening prognosis

— News, features, and commentary about cancer-related issues

Case shows importance of accurate preop diagnosis

News All Time

Blood Cancer's First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win

News, features, and commentary about cancer-related issues

More Evidence Ties Microplastics to Lung Cancer

Observational study shows greater microplastic burden in patients with lung malignancy

Nationwide Epinephrine Recall; FBI's Fauci Probe; Bruce Campbell's Cancer

Health news and commentary gathered by MedPage Today staff

9/11's Latest Wave of Cancers, 25 Years On

The health ramifications of the attack persist

Study Warns on Venetoclax in Double-Hit Lymphoma

Excess deaths seen in trial combining the BCL2 inhibitor with intensive initial regimen

Cancer Diagnosis, Then a Stroke; 9/11 Cancer Deaths; 'Grand Slam' Drug and Price

News, features, and commentary about cancer-related issues

Local Consolidative Therapy After Dual Immunotherapy Fizzles in Metastatic NSCLC

Overall survival favored nivolumab-ipilimumab alone in LONESTAR trial

Significant Survival Boost With Novel ADCs in Relapsed Small-Cell Lung Cancer

Death risk cut by 54% with B7-H3-targeting tambotatug pelitecan and risvutatug rezetecan

No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy

Non-significant 4-month PFS increase with sacituzumab govitecan-pembrolizumab, no OS benefit

Cancer Drug Shortages Continue With No Immediate Path Toward Relief

All responding NCCN members reported shortages, priorities identified but solutions still needed

Brain MRI Surveillance Alone Helps Preserve Cognition in Small Cell Lung Cancer

Omitting prophylactic cranial irradiation led to improved cognitive failure-free survival

Nurse Accused of Exorcism; Death After 8 Hours of Plastic Surgery; Top Cancer Months

Health news and commentary gathered by MedPage Today staff

Novel Drug Cuts Risk for Death by 44% in Squamous Lung Cancer Trial

If approved, immunotherapy gotistobart could offer a chemo-free option in second-line setting

Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy

Practice-changing median of 14.3 months with T-DXd, but caution over early unfavorable OS trend

Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial

Bispecific antibody and ADC together impress in early study

ROS1-Targeting Lung Cancer Drug Yields 90% Response Rate

Early efficacy among the highest seen in lung cancer, expert says

Early-life exposure to air and light pollution linked to increased risk of pediatric thyroid cancer

In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.

Participate and win cash vouchers

Get updates on the latest events happening around the world

2.

Triplet Could Become a New Standard in Tough-to-Treat CLL

3.

Dasatinib Fails to Improve Outcomes in CBF-AML

4.

Financial hardship common in patients with cancer

5.

New study links air pollution with higher rates of head and neck cancer

1.

Remote Hematology Follow-Up: Advancements, Clinical Implications, and Future Directions

2.

Red Blood Cell Aging and Clinical Implications

3.

Digital Oncology Ecosystems Integrating Longitudinal Patient Trajectories: Transforming Cancer Care through Data-Driven Innovation

4.

Tumor Evolution Under Treatment Pressure: Real-Time Tracking of Resistance and Clonal Selection

5.

A Visual Journey Through Penile Cancer: Examining the Impact of Photos

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Cancer Care: From Awareness to Recovery

2.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

3.

A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

4.

Optimizing Treatment Options in Advanced Urothelial Carcinoma

5.

Efficient Management of First line ALK-rearranged NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

Latest News

Rare Tumor in a Rare Location in Patient With Constipation

ASTRO: American Society for Radiation Oncology

A Surgical First for Removal of an Appendiceal Neoplasm

What's Behind the Mysterious Chest Pain in Bladder Cancer Patient?

Cancer Deaths Fall, Cases Rise; Diabetes and Cancer Risk; Vitamin C for Cancer

Benign or Malignant? No Way to Tell Radiologically

Todays Updates

Episode 177: Previewing the 2026 NEALS Annual Meeting Marco Meglio, Jinsy A. Andrews, MD, MSc, Nicholas Maragakis, MD

Todays Updates

Episode 177: Previewing the 2026 NEALS Annual Meeting Marco Meglio, Jinsy A. Andrews, MD, MSc, Nicholas Maragakis, MD

Latest News

News All Time

Blood Cancer's First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win

More Evidence Ties Microplastics to Lung Cancer

Nationwide Epinephrine Recall; FBI's Fauci Probe; Bruce Campbell's Cancer

9/11's Latest Wave of Cancers, 25 Years On

Study Warns on Venetoclax in Double-Hit Lymphoma

Cancer Diagnosis, Then a Stroke; 9/11 Cancer Deaths; 'Grand Slam' Drug and Price

Local Consolidative Therapy After Dual Immunotherapy Fizzles in Metastatic NSCLC

Significant Survival Boost With Novel ADCs in Relapsed Small-Cell Lung Cancer

No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy

Cancer Drug Shortages Continue With No Immediate Path Toward Relief

Brain MRI Surveillance Alone Helps Preserve Cognition in Small Cell Lung Cancer

Nurse Accused of Exorcism; Death After 8 Hours of Plastic Surgery; Top Cancer Months

Novel Drug Cuts Risk for Death by 44% in Squamous Lung Cancer Trial

Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy

Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial

ROS1-Targeting Lung Cancer Drug Yields 90% Response Rate

Recommended News For You